Hemorrhage

"Hemorrhage" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Bleeding or escape of blood from a vessel.

Descriptor ID	D006470
MeSH Number(s)	C23.550.414
Concept/Terms	Hemorrhage Hemorrhage Hemorrhages Bleeding

Below are MeSH descriptors whose meaning is more general than "Hemorrhage".

Diseases [C]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Hemorrhage [C23.550.414]

Below are MeSH descriptors whose meaning is related to "Hemorrhage".

Below are MeSH descriptors whose meaning is more specific than "Hemorrhage".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hemorrhage" by people in this website by year, and whether "Hemorrhage" was a major or minor topic of these publications.

Bar chart showing 454 publications over 30 distinct years, with a maximum of 33 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	5	3	8
1997	3	1	4
1998	7	0	7
1999	2	3	5
2000	2	1	3
2001	1	1	2
2002	3	5	8
2003	1	5	6
2004	5	5	10
2005	7	3	10
2006	4	4	8
2007	5	2	7
2008	6	6	12
2009	5	8	13
2010	2	7	9
2011	8	11	19
2012	6	9	15
2013	12	14	26
2014	8	14	22
2015	12	10	22
2016	15	9	24
2017	13	16	29
2018	14	17	31
2019	19	14	33
2020	9	19	28
2021	7	21	28
2022	0	25	25
2023	1	27	28
2024	4	7	11
2025	0	1	1

Below are the most recent publications written about "Hemorrhage" by people in Profiles.

Ibrahim A, Shalabi L, Zreigh S, Ramadan S, Mourad S, Eljadid G, Beshr M, Abdelaziz A, Elhadi M, Sabouret P, Mamas M. Comparative Efficacy and Safety of Low-Dose Direct Oral Anticoagulants Versus Dual Antiplatelet Therapy Following Left Atrial Appendage Occlusion in Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis. Catheter Cardiovasc Interv. 2025 05; 105(6):1311-1319.

View in: PubMed
Jason MJ, Marzec LN, Piccini JP, Shrader P, Pieper KS, Blanco RG, Fonarow GC, Gersh BJ, Ho PM, Hylek E, Kowey PR, Mahaffey KW, Steinberg BA, Peterson ED, Allen LA. Stroke-bleeding risk score pairings within individuals in the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Int J Cardiol. 2025 Feb 15; 421:132912.

View in: PubMed
Leung HHL, Ahmadi Z, Lee B, Casey J, Ratnasingam S, McKenzie SE, Perdomo J, Chong BH. Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments. Blood Adv. 2024 11 26; 8(22):5744-5752.

View in: PubMed
Istanbuly S, Matetic A, Bang V, Sharma K, Golwala H, Kheiri B, Osman M, Swamy P, Bharadwaj A, Mamas MA. Outcomes of 1.3 million patients undergoing percutaneous coronary intervention according to the presence of cancer and atrial fibrillation: a retrospective study. Croat Med J. 2024 Oct 31; 65(5):405-416.

View in: PubMed
Wurtzel JGT, Gray BD, Pak KY, Zhao X, Ma P, McKenzie SE, Tanujaya M, Rizzo V, Del Carpio-Cano F, Rao AK, Lee-Gau Chong P, Goldfinger LE. Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice. J Thromb Haemost. 2025 Jan; 23(1):108-122.

View in: PubMed
Ullah W, Sandhyavenu H, Taha A, Narayana Gowda S, Mukhtar M, Reddy Polam A, Zahid S, Fischman DL, Savage MP, Rao SV, Alkhouli M. Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A?Systematic Review and Network Meta-Analysis. J Am Heart Assoc. 2024 Oct 15; 13(20):e032490.

View in: PubMed
Halawi H, Sabawi MM, Rizk E, Mahmoud AA, Petkova JH, Hui SR, Srour N, Donahue KR. Bleeding outcomes in critically ill patients on heparin with discordant aPTT and anti-Xa activity. J Thromb Thrombolysis. 2025 Feb; 58(2):210-219.

View in: PubMed
Dafaalla M, Costa F, Kontopantelis E, Araya M, Kinnaird T, Micari A, Jia H, Mintz GS, Mamas MA. Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score. Eur Heart J. 2024 Sep 07; 45(34):3138-3148.

View in: PubMed
Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, Kamel H, Lewis BS, Cornel JH, Kowey PR, Horrow J, Strony J, Plotnikov AN, Li D, Weng S, Donahue J, Gibson CM, Steg PG, Mehran R, Weitz JI, Johnston SC, Hankey GJ, Harrington RA, Lam CSP. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024 Nov; 277:145-158.

View in: PubMed
Sainbayar E, Pham HN, Olson A, Ibrahim R, Grewal H, Salih M, Mamas MA, Lee K. Dual vs triple antithrombotic therapy in atrial fibrillation and acute coronary syndrome: An updated meta-analysis of randomized controlled trials. J Investig Med. 2024 12; 72(8):956-960.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement